Yaa-Hui Dong
Overview
Explore the profile of Yaa-Hui Dong including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
42
Citations
421
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lin T, Wang J, Wang G, Huang Y, Chen M, Dong Y, et al.
Front Pharmacol
. 2024 Dec;
15:1414221.
PMID: 39723254
Background: Although biological plausibility suggests that fluoroquinolones could lead to rhegmatogenous retinal detachment (RRD) through collagen degradation, real-world evidence on their relative risk of RRD is inconsistent, with limited information...
2.
Wung J, Hsu C, Wang C, Dong Y, Lin C, Wang S, et al.
Adv Pharmacol Pharm Sci
. 2024 Oct;
2024:9694592.
PMID: 39359455
Introduction: Pharmacokinetic studies have shown that rifampin reduces the levels of oral anticoagulants during the initiation of coadministration, raising concerns about an increased thrombotic risk, but there are limited comparative...
3.
Teng Y, Wang Y, Dong Y, Liu J
Breast Cancer Res Treat
. 2024 May;
206(2):437-439.
PMID: 38696023
No abstract available.
4.
Teng Y, Wang Y, Dong Y, Liu J
Breast Cancer Res Treat
. 2024 Mar;
205(3):619-631.
PMID: 38526687
Purpose: Early-onset breast cancer incidence has been increasing globally and in Taiwan. However, previous studies have not comprehensively examined how clinical and lifestyle characteristics influence the 5-year survival of breast...
5.
Pannoi T, Promchai C, Apiromruck P, Wongpraphairot S, Dong Y, Yang C, et al.
PeerJ
. 2024 Feb;
12:e16892.
PMID: 38371380
Background: Proton-pump inhibitors (PPIs) are prescribed to treat gastric acidrelated diseases, while they may also have potential risks to population health. Recent studies suggested that a potential mechanism explaining the...
6.
Dong Y, Wang J, Chang C, Lin J, Chen Y, Chen C, et al.
Clin Pharmacol Ther
. 2023 Nov;
115(1):147-157.
PMID: 37926942
Biological plausibility suggests that fluoroquinolones may lead to mitral valve regurgitation or aortic valve regurgitation (MR/AR) through a collagen degradation pathway. However, available real-world studies were limited and yielded inconsistent...
7.
Chen C, Pan S, Hsu C, Liu J, Kumamaru H, Dong Y
Respir Res
. 2023 Sep;
24(1):239.
PMID: 37775734
Background: Use of combinations of long-acting β agonists/long-acting muscarinic antagonists (LABA/LAMA) in patients with chronic obstructive pulmonary disease (COPD) is increasing. Nevertheless, existing evidence on cardiovascular risk associated with LABA/LAMA...
8.
Liao P, Pan S, Chen C, Deng C, Dong Y
Int J Chron Obstruct Pulmon Dis
. 2023 Apr;
18:553-563.
PMID: 37069844
Background: The clinical guideline recommends use of long-acting β2 agonists/long-acting muscarinic antagonists (LABA/LAMA) or long-acting β2 agonists/inhaled corticosteroids (LABA/ICS) combination therapies for patients with severe chronic obstructive pulmonary disease (COPD)....
9.
Lee Y, Dong Y, Yang W, Wu L, Lin J, Chang C
Front Pharmacol
. 2022 Sep;
13:869804.
PMID: 36176438
Both sodium glucose cotransporter 2 inhibitors (SGLT-2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) have cardiovascular protective effects in patients with type 2 diabetes mellitus. However, the comparative risk of GLP-1RA...
10.
Dong Y, Wu J, Chang C, Lin J, Wu L, Toh S
Pharmacotherapy
. 2022 May;
42(6):483-494.
PMID: 35508702
Study Objective: Clinical trials have suggested that glucagon-like peptide-1 receptor agonists (GLP-1RAs) may be associated with a higher risk of biliary-related diseases in patients with type 2 diabetes. Limited real-world...